Filgotinib Meets Primary Endpoints in Two Rheumatoid Arthritis Studies - Rheumatology Advisor

Filgotinib Meets Primary Endpoints in Two Rheumatoid Arthritis Studies  Rheumatology Advisor

Gilead Sciences and Galapagos NV announced that filgotinib met the primary and major secondary endpoints in the phase 3 FINCH 1 rheumatoid arthritis, ...